Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2011

TATAA Biocenter to Distribute TriLink’s CleanAmp Product Line

  • TATAA Biocenter will sell the line of CleanAmp™ Products produced by TriLink BioTechnologies for Hot Start PCR under a distribution agreement. The product line is reportedly designed to resolve common PCR problems such as primer dimer formation and mispriming.

    Products include CleanAmp dNTPs, designed to convert an assay to a Hot Start assay; CleanAmp 7-deaza-dGTP, a Hot Start tool intended for GC-rich target amplification; CleanAmp Primers for established assays; and CleanAmp Amidites for in-house synthesis of CleanAmp Primers.

    TriLink will add to its CleanAmp product line in April. It expects to roll out new, improved CleanAmp dNTPs. According to TriLink, dNTP chemistry enables better amplicon yield in endpoint PCR and earlier Cq values in fast-cycling real-time PCR.

    TATAA develops and performs a broad spectrum of hands-on qPCR courses worldwide. It also provides services for real-time PCR applications that include high-throughput qPCR analysis, primer and probe design and validation, data analysis, testing and evaluation of kits and instruments, and contract research to pharmaceutical and biotech companies.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »